Ionis Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 16 Posts
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Article By: Benzinga Saturday, April 27, 2019 6:05 PM EDT
Biotech stocks staged a recovery this week after being in the red in the previous two weeks.
In this article: BTX, BOLD, REGN, BIIB, GWPH, ALDX, HRTX, IONS, ADAP, NBRV, BHVN, NVS, SNY, RHHBY, ABBV
Read
Akcea, Ionis Slide After FDA Document Highlights Volanesorsen 'Safety Concerns'
Article By: The Fly Tuesday, May 8, 2018 12:51 PM EDT
Shares of Ionis Pharmaceuticals and its majority-owned spinout Akcea Therapeutics are sliding after the Food and Drug Administration posted its briefing document ahead of Thursday's meeting to discuss the latter's volanesorsen.
In this article: IONS Also: AKCA, ALNY
Read
Akcea Falls After FDA Panel Discusses 'Safety Concerns' Of Volanesorsen
Article By: The Fly Tuesday, May 8, 2018 9:37 AM EDT
Akcea Therapeutics and its controlling holder Ionis Pharmaceuticals are moving lower after an FDA panel posted its briefing document ahead of Thursday's meeting to discuss Akcea's volanesorsen.
In this article: AKCA, IONS
Read
4 Scorching Hot Momentum Stocks To Beat The Market
Article By: Zacks Investment Research Tuesday, October 31, 2017 1:25 AM EDT
Momentum is basically the tendency of winning stocks to keep winning and losing stocks to keep losing.
In this article: GBX, SKX, IONS, OSB
Read
Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
Article By: ChinaBio® Today Saturday, April 22, 2017 3:40 PM EDT
Tianjin CanSino Biologics, a vaccine developer, raised $65 Million in its latest funding round. Currently, CanSino is testing four products in Phase I to III clinical trials, conducted in North America, Africa and China respectively.
In this article: MRK, PFE, CELG, IONS, BGNE
Read
Novartis-Backed Ionis Subsidiary Akcea Maps A $100M IPO As It Steers A Lead Drug To Regulators
Article By: Lorimer Wilson Monday, March 27, 2017 6:16 PM EDT
Ionis Pharmaceuticals, Inc. subsidiary Akcea — a specialist in lipid disorders — is shooting for a $100 million IPO, with Novartis coming in to support the move with an extra $50 million to purchase a growing equity stake.
In this article: NVS, IONS
Read
Ionis Slides After Goldman Says Sell On 'Lackluster' Track Record
Article By: The Fly Friday, March 10, 2017 1:18 PM EDT
Shares of Ionis Pharmaceuticals are slipping after Goldman Sachs analyst Salveen Richter downgraded the stock to Sell, saying the company's antisense platform has yet to be fully optimized given the low rate of clinical success.
In this article: IONS Also: ALNY, NVS
Read
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains On Vertex Deal
Article By: Arpita Dutt Wednesday, March 8, 2017 9:08 AM EDT
A tweet kept the biotech industry on edge with President Donald Trump declaring that he is “working on a new system where there will be competition in the Drug Industry” and “pricing for the American people will come way down”.
In this article: CNCE, IONS, JUNO, CELG Also: VRTX, GILD, BIIB
Read
Ionis Pharmaceuticals Reports Positive Trial Results
Article By: KKD Healthcare Analytics Monday, March 6, 2017 12:46 PM EDT
Ionis Pharmaceuticals announced that the pivotal Phase 3 APPROACH study of volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome.
In this article: IONS
Read
AveXis Slides After Biogen, Ionis SMA Drug Approval
Article By: The Fly Tuesday, December 27, 2016 2:12 PM EDT
Shares of AveXis are slipping after Biogen and Ionis Pharmaceuticals received FDA approval for Spinraza, their treatment for spinal muscular atrophy, or SMA.
In this article: BIIB, IONS, AVXS
Read
On The Fly: Top Stock Stories For Monday
Article By: The Fly Monday, November 7, 2016 6:48 PM EDT
Stocks began the day sharply higher and the major averages continued to add to their gains from there, finishing with an advance of about 2%. In the process, the S&P broke its nine-day losing streak.
In this article: N, SYY, BIIB, ORCL, TROW, LC, WIN, NILE, IONS, BID, ELNK, HSNI, CHRS, ABBV
Read
Biotech ETFs Lead Q3 Rally: XBI Breaks Out
Article By: Rod Raynovich Thursday, September 22, 2016 8:00 PM EDT
The biotech sector is doing much better since BREXIT in late June despite a sell-off in late August. We are still trying to escape a bear market mentality because of the Q1 correction and concerns about drug prices.
In this article: AGN, JNJ, MDT, CPHD, ILMN, REGN, AMGN, BIIB, CELG, GILD, QGEN, XBI, XLV, Q, SRPT, BLUE, TSRO, IONS
Read
More Bullish Setups For The Risk-On Trader
Article By: Ryan Mallory Monday, July 18, 2016 1:04 PM EDT
The bulls are trying to start the week off right, with more upside. This is despite the failed coup attempt in Turkey over the weekend and more law enforcement officers being killed domestically.
In this article: AEP, AES, BAH, BC, CAT, CLR, DDD, DFS, ETN, HOT, ROK, TWX, LNG, CAVM, MDVN, AAPL, AKAM, AMZN, CSCO, GILD, ORCL, QCOM, WBA, IONS
Read
5 Biotech Takeover Targets That Could Get Bought Soon
Article By: Bret Jensen Saturday, June 11, 2016 1:31 PM EDT
Don’t let the resurgence in M&A in the biotech sector pass you by. Bret Jensen shares his top five picks for likely acquisition targets in biotech.
In this article: AGN, AZN, PFE, SGYP, SNY, VRX, ACAD, ANAC, MDVN, PGNX, XNPT, BIIB, TEVA, ABBV, CPXX, IONS
Read
Biotech Rally Fades But Plenty Of Big Movers: ASCO June 6
Article By: Rod Raynovich Saturday, May 28, 2016 6:23 PM EDT
The biotech rally fades after five days with the IBB down 0.49% and XBI down 1%. Biotech stocks were weak at the onset and could not come back but the sector is still up about 7% over five days.
In this article: GSK, ALNY, ARRY, IBB, CELG, XBI, XLV, JUNO, IONS, BMY, RHHBY, NERV, GWPH, ABBV
Read
1 to 16 of 16 Posts